Skip to main content
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC — Investor Relations & Filings

Ticker · ADAP ISIN · US00653A1079 LEI · 549300UUNWK8TRT5EW12 US Manufacturing
Open in API
Filings indexed 807 across all filing types
Latest filing 2016-03-17 Annual Report
Country GB United Kingdom
Listing US ADAP

About Adaptimmune Therapeutics PLC

https://www.adaptimmune.com/

Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company specializing in the development of novel T-cell receptor (TCR) T-cell therapies for cancer. The company utilizes a proprietary platform to engineer a patient's own T-cells to recognize and fight solid tumors. Its first FDA-approved therapy, Tecelra (afami-cel), is a treatment for advanced synovial sarcoma. Adaptimmune is advancing a robust pipeline of cell therapies, including preclinical programs targeting PRAME and CD70, as well as an allogeneic platform. The company's mission is to deliver transformative, potentially single-infusion treatments to reshape cancer care for patients with difficult-to-treat solid tumors.

Recent filings

Filing Released Lang Actions
20-F
Annual Report H2 2015
2016-03-17 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes an update on a clinical trial event and the resumption of recruitment after a safety review, which is an operational update rather than a financial report or earnings release. It does not contain financial statements or detailed financial data. The document is not an Annual Report, Earnings Release, or Interim Report. It is not related to board changes, capital updates, or voting results. The nature of the information is a regulatory announcement about a clinical trial event and safety review, fitting the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories. The document length is under 5,000 characters, and it is a standalone announcement rather than a report publication or certification. Therefore, the appropriate classification is Regulatory Filings (RNS).
2016-02-16 English
SC 13G
Major Shareholding Notification
2016-02-12 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated February 9, 2016, reporting the appointment of Dr. Gwendolyn Binder-Scholl as Chief Technology Officer. The content focuses on changes in the company's management team, specifically the departure and appointment of officers. There are no financial statements or earnings data, nor is it an announcement of a report publication. The document fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2016-02-12 English
Major Shareholding Notification 2016
Major Shareholding Notification
2016-02-12 English
ADAPTIMMUNE THERAPEUTICS PLC
Major Shareholding Notification
2016-02-10 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.